Denmark· DK-28106005317
Erlotinib "Sandoz"
A erlotinib product containing erlotinibhydrochlorid, registered in Denmark by Sandoz A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Erlotinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EB02 (erlotinib), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Erlotinib · ATC L01EB02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of erlotinib costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Erlotinib · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$102.78
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Erlotinibhydrochlorid
- Manufacturer
- Sandoz A/S
- Country
- Denmark (DK)
- ATC code
- L01EB02
- ATC class
- Erlotinib
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106005317
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
355 interactions on record for erlotinib.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Erlotinib · interactions on record
355 records
- 14 severe
- 192 moderate
- 2 minor
- 147 info
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EB02
Erlotinib, as other registers publish it.
- CanadaAPO-ERLOTINIBAPOTEX INC
- CanadaAPO-ERLOTINIBAPOTEX INC
- CanadaAPO-ERLOTINIBAPOTEX INC
- GermanyErlotevTad Pharma Gmbh
- United StatesErlotinibTeva Pharmaceuticals USA, Inc.
- United StatesErlotinibTeva Pharmaceuticals USA, Inc.
- United StatesErlotinibSun Pharmaceutical Industries, Inc.
- United StatesErlotinibAurobindo Pharma Limited
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/22b8d907-e0ef-45ba-a2f9-3e9e43c5db0d GET /v1/drugs/22b8d907-e0ef-45ba-a2f9-3e9e43c5db0d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "100 mg",
"auth_role": "CMS",
"dk_drugid": "28106005317",
"substance": "Erlotinibhydrochlorid",
"auth_procedure": "MRP",
"in_medicinpriser": false,
"registration_date_serial": "43116"
}See everything about erlotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.